Point72 Asia Singapore Pte. Ltd. Makes New Investment in HealthEquity, Inc. (NASDAQ:HQY)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 850 shares of the company’s stock, valued at approximately $73,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rise Advisors LLC acquired a new position in HealthEquity during the 1st quarter valued at about $28,000. International Assets Investment Management LLC acquired a new stake in HealthEquity during the 2nd quarter worth $35,000. YHB Investment Advisors Inc. bought a new stake in shares of HealthEquity during the 1st quarter valued at $40,000. Fidelis Capital Partners LLC acquired a new position in shares of HealthEquity in the 1st quarter valued at $42,000. Finally, Parallel Advisors LLC grew its stake in shares of HealthEquity by 255.5% during the fourth quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock worth $45,000 after purchasing an additional 488 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Buying and Selling

In related news, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the sale, the director now directly owns 4,823 shares in the company, valued at $387,093.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Frank Corvino sold 1,247 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares in the company, valued at $387,093.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares in the company, valued at approximately $7,168,952.34. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,952 shares of company stock valued at $3,526,147 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Bank of America cut their price objective on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Barrington Research reiterated an “outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. Wells Fargo & Company increased their target price on shares of HealthEquity from $107.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, June 20th. Finally, Raymond James increased their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $103.83.

HealthEquity Price Performance

Shares of HealthEquity stock opened at $83.09 on Friday. The business has a 50 day moving average of $76.47 and a 200 day moving average of $79.20. HealthEquity, Inc. has a 52 week low of $61.81 and a 52 week high of $88.26. The company has a market cap of $7.23 billion, a PE ratio of 90.32, a P/E/G ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. As a group, equities research analysts forecast that HealthEquity, Inc. will post 2.25 earnings per share for the current year.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.